secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001558370-25-011047
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor Q2 net loss $25.9M; FDA accepts all PLI observations; StealthX vaccine enters clinic
--------------------------------------------------------------------------------

- Net loss of $25.9M ($0.57 per share) for Q2 2025 vs $11.0M ($0.35) in Q2 2024; revenue $0 vs $4.0M.
- Cash, equivalents and securities $122.8M at June 30, 2025; expected to fund operations into Q4 2026.
- FDA accepted all 483 observations from Pre-License Inspection; Type A meeting scheduled for August 2025 to discuss Deramiocel BLA resubmission.
- FDA cleared IND for StealthX exosome-based vaccine; NIAID-initiated Phase 1 trial initiated in August 2025; first dosing imminent.
- HOPE-3 Phase 3 topline data expected Q4 2025; Orphan Drug Designation granted for Deramiocel in Becker muscular dystrophy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/0001558370-25-011047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer